EDIT editasmedicine.com Company Short-Term Debts

Brandmark of Editas (EDIT)

The price action for Editas Medicine, Inc. (EDIT) shown on this chart underscores its status as a holder of key CRISPR patents for developing high-precision treatments for blood pathologies. The specific short-term debt figure stands at 0.01. The brand is valued as one of the pioneers of gene therapy, while the market cautiously awaits the results of recent trials, maintaining confidence in the company's scientific foundation.

EDIT (Editas Medicine Inc) Short-Term Debt Volume history from 07/04/2022 to 11/01/2026

Summary analytical data breakdowns for Editas Corp (EDIT)

- stock price and consensus target price:
Stock Price Editas Medicine|EDIT - Average Forecast Price
- market capitalization data:
Market Capitalization Editas Medicine, Inc.|EDIT - Business Value
- business book valuation details:
Book Value per Share Editas Medicine|EDIT - Book Valuation of Business|Market Cap to Net Assets Ratio editasmedicine.com|EDIT - Aggregate Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Editas Medicine, Inc.|EDIT - Long-Term Debt to Capital|Short-Term Debt to Equity Editas Medicine, Inc.|EDIT - Company Total Debt Obligations|Debt to Book Value Editas Medicine, Inc.|EDIT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Editas Medicine|Quick Ratio editasmedicine.com
- net income and valuation multiples indicators:
EDIT - Company Net Income
Fundamental company analysis:Editas Medicine - EDIT
Manufactured products of Editas Medicine, Inc.

Short-term debts represent a set of obligations with a maturity period of up to twelve months, determining the issuer's current solvency. For Editas Medicine, Inc. (EDIT), this metric reflects the financial burden associated with developing CRISPR therapies for patients with blood and vision pathologies. By analyzing the short-term debt chart, an investor assesses the risk of a liquidity shortage. Liability dynamics must be compared with inflows from pharma partners, which allows for the determination of the business model's stability before drugs enter the market.

Competing companies

Tempus AI, Inc - Company Short-Term Debts|Short-Term Debt Qiagen NV|IONS: Company Short-Term Debts|Company Short-Term Indebtedness RGEN|RNA (Avidity Biosciences) - Company Short-Term Debts|crisprtx.com (CRSP) - Short-Term Debt Volume|Company Current Liabilities WGS (GeneDx)|Amount of Current Liabilities RARE|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|Company Short-Term Debts Sarepta Corp SRPT|TWST - Company Short-Term Debt|Short-Term Debt Volume 10xgenomics.com TXG|NTLA (Intellia Therapeutics, Inc.) - Company Current Liabilities|Stoke Therapeutics Inc - Company Short-Term Loans and Borrowings|Company Short-Term Debt BioLife Corp|Company Current Liabilities Wave Pharma (WVE)|Company Short-Term Debts MAZE|SION - Short-Term Debt|Company Short-Term Debts PRME (Prime Medicine)|TSHA: Company Short-Term Indebtedness|uniQure Corp - Company Short-Term Debts|Short-Term Debt Volume MeiraGTx Corp MGTX|RGNX: Company Short-Term Debts|Company Current Liabilities solidbio.com|OCGN (Ocugen) - Company Short-Term Debts|Pacific Biosciences of California, Inc. (PACB) - Short-Term Debt Volume|Company Short-Term Debt Benitec (BNTC)|Design Corp - Company Short-Term Indebtedness|Company Short-Term Debts RCKT (Rocket Pharmaceuticals)|4dmoleculartherapeutics.com (FDMT) - Short-Term Debt|LXEO: Company Current Liabilities|Company Short-Term Loans and Borrowings KRRO (Korro Bio, Inc.)|SLN: Company Short-Term Debts|PRQR - Short-Term Debt Volume|Company Short-Term Debt Codexis Inc|Company Short-Term Indebtedness SGMO (sangamo.com)|Company Short-Term Debts NAUT|Company Current Liabilities Metagenomi Inc. MGX|Precision BioSciences - Company Current Liabilities|Short-Term Debt Volume Generation Bio Co (GBIO)|Boundless Bio, Inc. - Company Short-Term Debts|Short-Term Debt Exicure, Inc.|IMNN: Company Short-Term Debts|Company Short-Term Indebtedness PHIO|MBIO (Mustang Bio Inc) - Company Short-Term Debts|TransCode (RNAZ) - Short-Term Debt Volume|Company Current Liabilities BNGO (Bionano Genomics, Inc.)|Amount of Current Liabilities APDN|Company Short-Term Debts BLUE (bluebird bio)|IPA: Company Short-Term Indebtedness|OMGA - Company Short-Term Debt|OMIC (Singular Genomics Corp) - Company Short-Term Indebtedness|RGLS: Company Short-Term Debts|syros.com (SYRS) - Company Short-Term Debts|TBIO (Telesis Bio) - Company Short-Term Debts|Short-Term Debt TRACON Pharmaceuticals Inc. TCON|Company Short-Term Debts UBX